Navigation Links
Paul Capital Partners Promotes Ken Macleod To Partner
Date:7/23/2008

--Reflects Fund's Commitment to Meet the Financing Needs of European and

Asian Healthcare Companies and Institutions--

NEW YORK, July 24 /PRNewswire/ -- Paul Capital Partners today announced that Ken Macleod, Ph.D., has been promoted to Partner. Based in Paul Capital's London office, Dr. Macleod is responsible for sourcing, evaluating and negotiating European and Asian healthcare investment opportunities for the Paul Capital Healthcare funds.

"Since he joined Paul Capital four years ago, Ken has strengthened our presence in the European and Asian healthcare markets and helped us form many mutually beneficial partnerships," said Walter Flamenbaum, M.D., a Partner of Paul Capital Partners. "He embodies our commitment to helping healthcare companies, institutions and inventors advance their goals by identifying strategic solutions to their financial and asset management needs. Ken's promotion to Partner reflects his demonstrated ability to identify promising healthcare investment opportunities and underscores Paul Capital's dedication to expanding its position in the global healthcare arena."

Most recently, in April 2008, Paul Capital Healthcare invested up to $28 million in Plethora Solutions Holdings PLC and euro 18.4 million in Vernalis plc, both of which are based in the U.K. To date, the Paul Capital Healthcare funds have invested $395 million in 14 transactions in Europe and Asia.

"A growing number of European and Asian healthcare companies and institutions recognize that in order to realize their innovative potential they require an equally innovative approach to creating value and accessing capital," said Dr. Macleod. "With more than $940 million committed to 37 healthcare investments, and similar leadership in the areas of private equity secondaries and venture capital funds of funds, Paul Capital provides funds that help leading-edge companies, institutions and individuals meet diverse strategic objectives. I am very pleased to become a partner of this highly regarded team."

Dr. Macleod provides a strong operational background in the pharmaceutical and biotechnology industries, where he previously held senior management positions over a 15-year career at Serono, Abbott Laboratories and Beecham Pharmaceuticals. Prior to joining Paul Capital Partners, Dr. Macleod was a Venture Partner at Schroder Ventures Life Sciences where he was responsible for deal sourcing, evaluation and negotiation of pharmaceutical investment opportunities. Dr. Macleod earned his Ph.D. from the University of York, UK and his B.Sc. with honors in Biology from the University of Manchester, UK.

About Paul Capital Partners and Paul Capital Healthcare

Founded in 1991, Paul Capital manages $6.6 billion in capital commitments for its three investment platforms that include private equity secondaries, healthcare royalty and revenue interests, and venture capital fund of funds. The firm has offices in Hong Kong, London, New York, Paris, San Francisco, Sao Paulo and Toronto.

Through its funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with more than $1.4 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than $940 million in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at http://www.paulcapitalhealthcare.com.

Contact:

Paul Capital Partners

Ken Macleod, Partner

Tel: +44(0)20-7514-0754

Email: kmacleod@paulcap.com

Joshua Glaser, Director of Investor Relations

Tel: +1-646-264-1169

Email: jglaser@paulcap.com

Lazar Partners

Stephanie Seiler

Tel: +1-646-871-8487

Tel: +1-206-713-0124

Email: sseiler@lazarpartners.com


'/>"/>
SOURCE Paul Capital Partners
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
4. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. Advanced Life Sciences Joins NASDAQ Capital Market
9. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
10. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
11. Caxton-Iseman Capital Acquires Conney Safety Products, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: